Peregrine Capital Management LLC Has $6.54 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Peregrine Capital Management LLC increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 28.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 53,804 shares of the biotechnology company’s stock after buying an additional 11,965 shares during the quarter. Peregrine Capital Management LLC owned 0.06% of Sarepta Therapeutics worth $6,542,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SRPT. Manchester Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. increased its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank increased its stake in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $36,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $105.35 on Wednesday. Sarepta Therapeutics, Inc. has a 12-month low of $101.15 and a 12-month high of $173.25. The company’s 50 day moving average price is $118.57 and its two-hundred day moving average price is $124.07. The firm has a market cap of $10.06 billion, a PE ratio of 84.28 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Guggenheim increased their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Robert W. Baird decreased their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Finally, Evercore ISI dropped their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $176.77.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.